Cygnus Biosciences (Beijing) Co., Ltd. is a national high-tech enterprise integrating R&D, conversion, production, and marketing of gene sequencing technology. Founded by Academician Xie Xiaoliang, Professor Huang Yanyi, and Dr. Chen Zitian's team, the company specializes in the research, development, manufacturing, and marketing of gene sequencing instruments, reagents, consumables, and gene testing services. Cygnus is dedicated to providing simpler, more precise, and efficient gene sequencing tools and solutions for various fields in the life sciences, including biological research, medical diagnosis, drug development, animal and plant breeding, customs, disease control, forensic science, and evolutionary research.
More
Proprietary fluorogenic sequencing chemistry with high on-off ratio
Simultaneous DNA polymerization, label cleavage and fluorescence generation
One-step chemistry without molecular scars to achieve long read length
Unique SBS strategy using 3 rounds of dual-base flowgrams combining chemical and information technologies
Four bases encoded in 3 bits with 50% information redundancy
Proprietary ECC algorithm enhances accuracy geometrically
Two bases areadded in every cycle to eliminate dark cycles
One-round sequencing of M (A/C) and K (G/T) suffices analysis
Turn-around time as low as 6.5 h in BitSeq, 1/3 of conventional methods
Suitable for counting applications such as CNV, NIPT and RNA-seq
10-18 L Attoliter-Scale Microreactor Array Chip (Attoliter Reactor Array)
AttoSeal Technology 10× Extreme Reagent Savings
Fluorescence Switching Ratio10000×
No Molecular Scars
Monochromatic fluorescence
GS100 Sequencing Platform, featuring BitSeq ultra-fast sequencing speed, Q40 standard accuracy, great compatibility, and simple hand-on procedure, is suitable for applications such as NIPT, PGT-A, CNV, mNGS, tNGS, Tumor, etc.
Genetic testing for hereditary early-onset coronary heart disease and individualized medication evaluation is a genetic testing product based on Cygnus sequencer's S100 gene sequencer. It mainly detects genes associated with the risk of early-onset coronary heart disease, including LDLR, LDLRAP1, PCSK9, ABCG5, ABCG8, and APOB. This product is helpful for the early detection and prevention of the disease. Additionally, it also analyzes statin-related genes to evaluate the risk of adverse reactions and the effectiveness of statin drugs
